Cargando…

The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease

The major pulmonary complication of rheumatoid arthritis (RA) is interstitial lung disease (ILD), which causes significant morbidity and mortality and influences the natural course of disease. Recent advances in the management of arthritis have improved patient outcomes. However, exceptionally high...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Minrui, Matteson, Eric L., Abril, Andy, Distler, Jörg H.W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Interstitial Lung Disease in Autoimmune Rheumatic Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852164/ https://www.ncbi.nlm.nih.gov/pubmed/35186127 http://dx.doi.org/10.1177/1759720X221074457

Ejemplares similares

The role of antifibrotic therapies in the treatment of systemic sclerosis–associated interstitial lung disease
por: Boleto, Gonçalo, et al.
Publicado: (2022)

Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease
por: Wilfong, Erin M., et al.
Publicado: (2021)

Biomarkers for interstitial lung disease and acute-onset diffuse interstitial lung disease in rheumatoid arthritis
por: Furukawa, Hiroshi, et al.
Publicado: (2021)

Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders
por: Panagopoulos, Panagiotis, et al.
Publicado: (2021)

Interstitial lung disease pathology in systemic sclerosis
por: Konopka, Kristine E., et al.
Publicado: (2021)

Systemic sclerosis associated interstitial lung disease: a survey of current practices in France
por: Nicolas, Amélie, et al.
Publicado: (2023)

Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders
por: Kuwana, Masataka, et al.
Publicado: (2021)

Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all
por: Spierings, J., et al.
Publicado: (2021)

Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review
por: Campochiaro, Corrado, et al.
Publicado: (2022)

Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren’s syndrome: a literature review
por: Depascale, Roberto, et al.
Publicado: (2021)

Reliability and responsiveness of the D12 and validity of its scores as a measure of dyspnoea severity in patients with rheumatoid arthritis-related interstitial lung disease
por: Swigris, Jeffrey J, et al.
Publicado: (2023)

Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
por: Proesmans, V. L. J., et al.
Publicado: (2019)

Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis
por: Wright, William Alexander, et al.
Publicado: (2021)

National data on prevalence of idiopathic pulmonary fibrosis and antifibrotic drug use in Finnish specialised care
por: Salonen, Johanna, et al.
Publicado: (2022)

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials
por: Saketkoo, Lesley Ann, et al.
Publicado: (2014)

Analytic Morphomics in Myositis-Related Interstitial Lung Disease
por: O’Mahony, Alexander T., et al.
Publicado: (2023)

Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)
por: Wild, Jim M, et al.
Publicado: (2021)

Macrophage-derived exosomes attenuate fibrosis in airway epithelial cells through delivery of antifibrotic miR-142-3p
por: Guiot, Julien, et al.
Publicado: (2020)

Diagnoses and treatments for participants with interstitial lung abnormalities detected in the Yorkshire Lung Screening Trial
por: Upperton, Sara, et al.
Publicado: (2023)

Feasibility of cardiopulmonary exercise testing in interstitial lung disease: the PETFIB study
por: Tomlinson, Owen, et al.
Publicado: (2021)

Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases
por: Salonen, Johanna, et al.
Publicado: (2020)

Telehealth for patients with interstitial lung diseases (ILD): results of an international survey of clinicians
por: Althobiani, Malik, et al.
Publicado: (2021)

Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review
por: Shah Gupta, Rikisha, et al.
Publicado: (2023)

Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study
por: Troy, Lauren K, et al.
Publicado: (2019)

Predictors of postoperative acute exacerbation of interstitial lung disease: a case–control study
por: Hosoki, Keisuke, et al.
Publicado: (2020)

The King’s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference
por: Sinha, Aish, et al.
Publicado: (2019)

Patient perspectives on home-spirometry in interstitial lung disease: a qualitative co-designed study
por: Mandizha, Jessica, et al.
Publicado: (2023)

Defining the pathway to timely diagnosis and treatment of interstitial lung disease: a US Delphi survey
por: Case, Amy Hajari, et al.
Publicado: (2023)

Mediators of systemic sclerosis-associated interstitial lung disease (SSc-ILD): systematic review and meta-analyses
por: Fields, Aislin, et al.
Publicado: (2023)

CD4+T cells in ageing-associated interstitial lung abnormalities show evidence of pro-inflammatory phenotypic and functional profile
por: Machahua, Carlos, et al.
Publicado: (2021)

Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis
por: Nayebirad, Sepehr, et al.
Publicado: (2023)

Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy
por: Sgalla, Giacomo, et al.
Publicado: (2015)

Gremlin-1 for the Differential Diagnosis of Idiopathic Pulmonary Fibrosis Versus Other Interstitial Lung Diseases: A Clinical and Pathophysiological Analysis
por: Aoshima, Yoichiro, et al.
Publicado: (2021)

In vivo polarisation sensitive optical coherence tomography for fibrosis assessment in interstitial lung disease: a prospective, exploratory, observational study
por: Vaselli, Margherita, et al.
Publicado: (2023)

Computed Tomography Findings as Determinants of Local and Systemic Inflammation Biomarkers in Interstitial Lung Diseases: A Retrospective Registry-Based Descriptive Study
por: Lang, David, et al.
Publicado: (2021)

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial
por: Maher, Toby M, et al.
Publicado: (2018)

Specialist palliative care, psychology, interstitial lung disease (ILD) multidisciplinary team meeting: a novel model to address palliative care needs
por: Barratt, Shaney L, et al.
Publicado: (2018)

Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases
por: Swigris, Jeffrey J, et al.
Publicado: (2022)

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease
por: Flaherty, Kevin R, et al.
Publicado: (2017)

Clinicoserological features of antisynthetase syndrome (ASyS)-associated interstitial lung disease presenting to respiratory services: comparison with idiopathic pulmonary fibrosis and ASyS diagnosed in rheumatology services
por: Barratt, Shaney L, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f7k5pblegqnprrig4sl17tlomj